The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3826-3832

  Chun, Kyung Hee ^a   Benbrook, Doris M ^b   Berlin, K Darrell ^c   Hong, Waun Ki ^a   Lotan, Reuben ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[(4 NITROPHENYL)AMINO][(2,2,4,4 TETRAMETHYLTHIOCHROMAN 6 YL)AMINO]METHANE 1 THIONE; BUTYLATED HYDROXYANISOLE; CYCLOSPORIN A; CYTOCHROME C; FENRETINIDE; REACTIVE OXYGEN METABOLITE; RETINOIC ACID RECEPTOR; RETINOID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CASPASES; CHROMANS; ENZYME ACTIVATION; HEAD AND NECK NEOPLASMS; HUMANS; INTRACELLULAR MEMBRANES; KINETICS; MEMBRANE POTENTIALS; MITOCHONDRIA; PERMEABILITY; RETINOIDS; THIONES; TUMOR CELLS, CULTURED;

EID: 0038755690     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Moon, R. C., Mehta, R. G., and Rao, K. J. V. N. Retinoids and cancer in experimental animals. In: H. M. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids, pp. 573-595. New York: Raven Press, 1994.
2. Hong, W. K., and Itri, L. M. Retinoids and human cancer. In: H. M. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids, pp. 597-658. New York: Raven Press, 1994.
3. Lotan, R. Retinoids in cancer chemoprevention. FASEB J., 10: 1031-1039, 1996.
4. Evans, T. R. J., and Kaye, S. Retinoids: present role and future potential. Br. J. Cancer, 80: 1-8, 1999.
5. Gudas, L. J., Sporn, M. B., and Roberts, A. B. The Cellular biology and biochemistry of the retinoids. In: H. M. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids, pp. 443-520. New York: Raven Press, 1994.
6. Gottardis, M. M., Lamph, W. W., Shalinsky, D. R., Wellstein, A., and Heyman, R. A. The efficacy of 9-cis-retinoic acid in experimental models of cancer. Breast Cancer Res. Treat., 38: 85-96, 1996.
7. Shalinsky, D. R., Bischoff, E. D., Lamph, W. W., Zhang, L., Boehm, M. F., Davies, P. J., Nadzan, A. M., and Heyman, R. A. A novel retinoic acid receptor-selective retinoid. ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res., 57: 162-168, 1997.
8. Bischoff, E. D., Gottardis, M. M., Moon, T. E., Heyman, R. A., and Lamph, W. W. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res., 58: 479-484, 1998.
9. Shalinsky, D. R., Bischoff, E. D., Gregory, M. L., Lamph, W. W., Heyman, R. A., Hayes, J. S., Thomazy, V., and Davies, P. J. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin. Cancer. Res., 3: 511-520, 1996.
10. Lotan, R. Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res., 54 (Suppl.): 1987s-1990s, 1994.
11. Oridate, N., Lotan, R., and Lotan, D. Reconstituted basement membrane (Matrigel): a useful semisolid medium for growth of tumor cell colonies. In Vitro Cell Dev. Biol. Anim., 4: 192-193, 1994.
12. Lotan, R. Squamous cell differentiation markers in normal, premalignant, and malignant epithelium: effects of retinoids. J. Cell. Biochem. Suppl., 17: 167-174, 1993.
13. Sun, S-Y., Yue, P., Mao, L., Dawson, M. I., Shroot, B., Lamph, W. W., Heyman, R. A., Chandraratna, R. A. S., Shudo, K., Hong, W. K., and Lotan, R. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin. Cancer Res., 6: 1563-1573, 2000.
14. Sun, S-Y., Li, W., Yue, P., Hong, W. K., and Lotan, R. Mediation of N-(4-hydoxyphenyl) retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res., 59: 2493-2498, 1999.
15. Mariani, L., Formelli, F., De Palo, G., Manzari, A., Camerini, T., Campa, T., Di Mauro, M. G., Crippa, A., Delle Grottaglie, M., Del Vecchio, M., Marubini, E., Costa, A., and Veronesi, U. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability. Tumorigenesis, 82: 444-449, 1996.
16. Benbrook, D. M. Refining retinoids with heteroatoms. Minirev. Med. Chem., 2: 271-277, 2002.
17. Collins, M. D., and Bao, G. E. Teratology of retinoids. Annu. Rev. Pharmacol. Toxicol., 39: 399-430, 1999.
18. Elmazar, M. M., Ruhl, R., and Nau, H. Synergistic teratogenic effects induced by retinoids in mice by coadministration of a RARα- or RARγ-selective agonist with a RXR-selective agonist. Toxicol. Appl. Pharmacol., 170: 2-9, 2001.
19. Benbrook, D. M., Madler, M. M., Spruce, L. W., Birckbichler, P. J., Nelson, E. C., Subramanian, S., Weerasekare, G. M., Gale, J. B., Patterson M. K. Jr., Wang, B., Wang, W., Lu, S., Rowland, T. C., DiSivestro, P., Lindamood, C., III, Hill, D. L., and Berlin, K. D. Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. J. Med. Chem., 40: 3567-3583, 1997.
20. Dhar, A., Liu, S., Klucik, J., Berlin, K. D., Madler, M. M., Lu, S., Ivey, R. T., Zacheis, D., Brown, C. W., Nelson, E. C., Birckbichler, P. J., and Benbrook, D. M. Synthesis, structure-activity relationships, and RARγ-ligand interactions of nitrogen heteroarotinoids. J. Med. Chem., 42: 3602-3614, 1999.
21. Zacheis, D., Dhar, A., Lu, S., Madler, M. M., Klucik, J., Brown, C. W., Liu, S., Clement, F., Subramanian, S., Weerasekare, G. M., Berlin, K. D., Gold, M. A., Houck, J. R., Jr., Fountain, K. R., and Benbrook, D. M. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J. Med. Chem., 42: 4434-4445, 1999.
22. Guruswamy, S., Lightfoot, S., Gold, M. A., Hassan, R., Berlin, K. D., Ivey, R. T., and Benbrook, D. M. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J. Natl. Cancer Inst. (Bethesda), 93: 516-525, 2001.
23. Lala, D. S., Mukherjee, R., Schulman, I. G., Koch, S. S., Dardashti, L. J., Nadzan, A. M., Croston, G. E., Evans, R. M., and Heyman, R. A. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature (Lond.), 383: 450-453, 1996.
24. Agarwal, C., Chandraratna, R. A., Johnson, A. T., Rorke, E. A., and Eckert, R. L. AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. J. Biol. Chem., 271: 12209-12212, 1996.
25. Oridate, N., Suzuki, S., Higuchi, M., Mitchell, M. F., Hong, W. K., and Lotan, R. Involvement of ROS in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. J. Natl. Cancer Inst. (Bethesda), 89: 1191-1198, 1997.
26. Higuchi, M., Honda, T., Proske, R. J., and Yeh, E. T. Regulation of ROS-induced apoptosis and necrosis by caspase 3-like proteases. Oncogene, 17: 2753-2760, 1998.
27. Suzuki, S., Higuchi, M., Proske, R. J., Oridate, N., Hong, W. K., and Lotan, R. Implication of mitochondria-derived ROS, cytochrome c and caspase-3 in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. Oncogene, 18: 6380-6387, 1999.
28. Marchetti, P., Zamzami, N., Joseph, B., Schraen-Maschke, S., Mereau-Richard, C., Costantini, P., Metivier, D., Susin, S. A., Kroemer, G., and Formstecher, P. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res., 59: 6257-6266, 1999.
29. Hoyt, K. R., Sharma, T. A., and Reynolds, I. J. Trifluoperazine and dibucaine-induced inhibition of glutamate-induced mitochondrial depolarization in rat cultured forebrain neurones. Br. J. Pharmacol., 122: 803-808, 1997.
30. Park, S. H., Gray, W. C., Hernandez, I., Jacobs, M., Ord, R. A., Sutharalingam, M., Smith, R. G., Van Echo, D. A., Wu, S., and Conley, B. A. Phase I trial of all-trans-retinoic acid in patients with treated head and neck squamous carcinoma. Clin. Cancer Res., 6: 847-854, 2000.
31. Soignet, S. L., Miller, V. A., Pfister, D. G., Bienvenu, B. J., Ho, R., Parker, B. A., Amyotte, S. A., Cato, A., III, and Warrell, R. P., Jr. Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550). Clin. Cancer Res., 6: 1731-1735, 2000.
32. Younes, A., Cristofanilli, M., McLaughlin, P., Hagemeister, F. B., Weber, D., Mesina, O., and Cabanillas, F. Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma. Leuk. Lymphoma, 40: 79-85, 2000.
33. Spruce, L. W., Gale, J. B., Berlin, K. D., Verma, A. K., Breitman, T. R., Ji, X. H., and van der Helm, D. Novel heteroarotinoids: synthesis and biological activity. J. Med. Chem., 34: 430-439, 1991.
34. Benbrook, D. M., Subramanian, S., Gale, J. B., Liu, S., Brown, C. W., Boehm, M. F., and Berlin, K. D. Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. J. Med. Chem., 41: 3753-3757, 1998.
35. Simoni, D., Roberti, M., Invidiata, F. P., Rondanin, R., Baruchello, R., Malagutti, C., Mazzali, A., Rossi, M., Grimaudo, S., Capon, F., Dusonchet, L., Meli, M., Raimondi, M. V., Landino, M., D'Alessandro, N., Tolomeo, M., Arindam, D., Lu, S., and Benbrook, D. M. Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells. J. Med. Chem., 44: 2308-2318, 2001.
36. Lotan, R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J. Natl. Cancer Inst. (Bethesda), 87: 1655-1657, 1995.
37. Delia, D., Aiello, A., Lombardi, L., Pelicci, P. G., Grignani, F., Grignani, F., Formelli, F., Menard, S., Costa, A., and Veronesi, U. N-(4-Hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res., 53: 6036-6041, 1993.
38. Shyu, R. Y., Lin, D. Y., Reichert, U., and Jiang, S. Y. Synthetic retinoid CD437 induces cell-dependent cycle arrest by differential regulation of cell cycle associated proteins. Anticancer Res., 22: 2757-2764, 2002.
39. Erjala, K., Pulkkinen, J., Kulmala, J., Alanen, K., and Grenman, R. Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in vitro. Anticancer Res., 22: 3135-3142, 2002.
40. 2-M cell cycle arrest, activation of caspase 8 or caspase 9 and synergy with APO2/TRAIL. Blood, 101: 4078-4087, 2003.
41. Hail, N., Jr., and Lotan, R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide. J. Biol. Chem., 276: 45614-45621, 2001.
42. Remacle, J., Raes, M., Toussaint, O., Renard, P., and Rao, G. Low levels of ROS as modulators of cell function. Mutat. Res., 316: 103-122, 1995.
43. Buttke, T. M., and Sandstrom, P. A. Oxidative stress as a mediator of apoptosis. Immunol. Today, 15: 7-10, 1994.
44. Meyer, M., Schreck, R., and Baeuerle, P. A. H2O2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J., 12: 2005-2015, 1993.
45. Schulze-Osthoff, K., Beyaert, R., Vandevoorde, V., Haegeman, G., and Fiers, W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J., 12: 3095-30104, 1993.
46. Ohba, M., Shibanuma, M., Kuroki, T., and Nose, K. Production of hydrogen peroxide by transforming growth factor-β1 and its involvement in induction of egr-1 in mouse osteoblastic cells. J. Cell. Biol., 126: 1079-1088, 1994.
47. Chinnaiyan, A. M., O'Rourke, K., Lane, B. R., and Dixit, V. M. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science (Wash. DC), 275: 1122-1126, 1997.
48. Connern, C. P., and Halestrap, A. P. Purification and N-terminal sequencing of peptidyl-prolyl cis-trans-isomerase from rat liver mitochondrial matrix reveals the existence of a distinct mitochondrial cyclophilin. Biochem. J., 284: 381-385, 1992.
49. Crompton, M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J., 341: 233-249, 1999.
50. Halestrap, A. P., McStay, G. P., and Clarke, S. J. The permeability transition pore complex: another view. Biochimie, 84: 153-166, 2002.
51. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Wash. DC), 281: 1309-1312, 1998.
52. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997.
53. Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90: 405-413, 1997.
54. Chinnaiyan, A. M., Chaudhary, D., O'Rourke, K., Koonin, E. V., and Dixit, V. M. Role of CED-4 in the activation of CED-3. Nature (Lond.), 388: 728-729, 1997.